The effect of G-CSF used after allogeneic hematopoietic stem cell transplantation on engraftment times and platelet suspension replacement numbers

dc.authoridUYSAL, AYŞE/0000-0002-5581-8104
dc.authoridSARICI, Ahmet/0000-0002-5916-0119
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridBİÇİM, SOYKAN/0000-0001-7498-344X
dc.authoridKAYA, Emin/0000-0001-8605-8497
dc.authoridkeser, muhammed furkan/0000-0002-4524-9761
dc.authorwosidUYSAL, AYŞE/HJB-3073-2022
dc.authorwosidSARICI, Ahmet/ABI-7512-2020
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.authorwosidBİÇİM, SOYKAN/ACZ-6163-2022
dc.authorwosidKAYA, Emin/W-2951-2017
dc.contributor.authorSarici, Ahmet
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorKuku, Irfan
dc.contributor.authorKaya, Emin
dc.contributor.authorBerber, Ilhami
dc.contributor.authorBicim, Soykan
dc.contributor.authorHidayet, Emine
dc.date.accessioned2024-08-04T20:52:05Z
dc.date.available2024-08-04T20:52:05Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: With the use of granulocyte colony stimulating factor (G-CSF) after allogeneic hematopoietic stem cell transplantation (HSCT), the duration of neutrophil engraftment and hospitalization were shortened. How-ever, there is no consensus on the effect of G-CSF on platelet engraftment time. The primary aim of our study is to determine the effect of G-CSF use on platelet engraftment time after HSCT. Secondary purposes are to determine the number of platelet suspension, number of erythrocyte suspension and incidence of acute graft versus disease after HSCT. Material and methods: Patients who had allogeneic stem cell transplantation at our center between 01.01.2011 and 01.01.2022 were retrospectively analyzed. Patients were divided into 2 groups as those who received and did not receive G-CSF after transplantation. Results: A total of 64 patients were included. While 32 patients were given post-HSCT G-CSF support, the other 32 patients were not given. Neutrophil engraftment time and length of hospital stay were shorter in the group receiving G-CSF (p < 0.05). Platelet engraftment time was shorter in the group that did not receive G-CSF (p < 0.05). The incidence of acute GVHD of the patients in group 1 tended to be higher than the patients in group 2 (40.6 % vs 15.6 %, p = 0.052). Post-HSCT platelet suspension was less in the group that did not receive G-CSF, but this difference was not statistically significant (p = 0.173). Conclusion: While the positive effect of post HSCT G-CSF use on duration of neutrophil engraftment and hospi-talization is evident, its effects on platelet engraftment need to be investigated.en_US
dc.identifier.doi10.1016/j.transci.2022.103482
dc.identifier.issn1473-0502
dc.identifier.issn1878-1683
dc.identifier.issue6en_US
dc.identifier.pmid35718683en_US
dc.identifier.scopus2-s2.0-85132700882en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2022.103482
dc.identifier.urihttps://hdl.handle.net/11616/100741
dc.identifier.volume61en_US
dc.identifier.wosWOS:000916052800014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHematopoietic stem cell transplantationen_US
dc.subjectThrombocyte engraftment timeen_US
dc.subjectErythrocyte and thrombocyte replacementen_US
dc.subjectnumberen_US
dc.subjectG-CSFen_US
dc.subjectAcute graft versus host diseaseen_US
dc.titleThe effect of G-CSF used after allogeneic hematopoietic stem cell transplantation on engraftment times and platelet suspension replacement numbersen_US
dc.typeArticleen_US

Dosyalar